Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000427 · ClinicalTrials.gov registry record · Phase 2
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
A Phase 2 study of Relapsed/Refractory Philadelphia Positive B-precursor ALL, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT02000427 is a Phase 2 study of Relapsed/Refractory Philadelphia Positive B-precursor ALL that has completed, run by Amgen. The registered enrollment target is 45 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT02000427, a Phase 2 study of Relapsed/Refractory Philadelphia Positive B-precursor ALL, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh\*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.
Conditions Studied
Interventions
- DRUG Blinatumomab
Study Locations (20)
Other
- Research Site - Nantes
- Research Site - Paris
- Research Site - Toulouse
- Research Site - Berlin
- Research Site - Essen
- Research Site - Frankfurt am Main
- Research Site - Würzburg
- Research Site - Bergamo
- Research Site - Bologna
- Research Site - Roma
- Research Site - Venezia
- Research Site - Verona
California
- Research Site - Duarte
- Research Site - La Jolla
Georgia
- Research Site - Atlanta
Minnesota
- Research Site - Rochester
Missouri
- Research Site - St Louis
New York
- Research Site - New York
North Carolina
- Research Site - Durham
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-01-03 |
| Est. Completion | 2017-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02000427
The ClinicalTrials.gov registry entry for NCT02000427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Philadelphia Positive B-precursor ALL appearing as the primary indexed condition, and to 1 intervention - of which Blinatumomab is the first listed.
NCT02000427 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02000427 about?
NCT02000427 is a clinical study titled "Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia". The primary objective is to evaluate the rate of complete remission/complete remission with partial hematological recovery (CRh\*) in adults with relapsed/refractory Philadelphia chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive blinatumomab.
What is the current status of trial NCT02000427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-01-03. Estimated completion is 2017-01-06.
What conditions does trial NCT02000427 study?
This clinical trial studies the following conditions: Relapsed/Refractory Philadelphia Positive B-precursor ALL.
What interventions are being tested in trial NCT02000427?
The interventions under investigation include: Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT02000427?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02000427 being conducted?
This trial has 20 study locations across California, Georgia, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.